PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40644736,Discriminating capacity of the ASAS health index in patients with axial spondyloarthritis treated with ixekizumab.,2025,N/A,"Eli Lilly and Company, 893 Delaware St, Indianapolis, Indiana 46225, USA.",uta.kiltz@elisabethgruppe.de
40644526,Structural elucidation of the haptoglobin-hemoglobin clearance mechanism by macrophage scavenger receptor CD163.,2025,N/A,"BioMedicine Design, Pfizer, Inc., La Jolla, California, United States of America.; BioMedicine Design, Pfizer, Inc., Cambridge, Massachusetts, United States of America.",
40644466,Evaluation of adverse events and comorbidity exacerbation following the COVID-19 booster dose: A national survey among randomly-selected booster recipients.,2025,N/A,,
40643842,"Broad Impact of Bowel Urgency in Ulcerative Colitis and Crohn's Disease: US, European, and Japanese Patient and Healthcare Professional Perspectives from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey.",2025,N/A,"Eli Lilly and Company, Indianapolis, USA.",drubin@bsd.uchicago.edu
40643788,Comparative Efficacy of Pharmacological Interventions for Heart Failure with Reduced Ejection Fraction Between Asian and White Patients: A Meta-analysis of Randomized Controlled Trials.,2025,N/A,"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1889 Museum Road, DSIT 6004, Gainesville, FL, 32606, USA.; Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1889 Museum Road, DSIT 6004, Gainesville, FL, 32606, USA. guoj1@ufl.edu.",guoj1@ufl.edu
